Healthcare Marketing Compliance Intelligence
ClinicShield scans your website against 110 FDA, FTC, and platform compliance rules — the same violation patterns the FDA cites when it decides who gets a warning letter.
LATESTOn April 30, 2026, the FDA proposed permanently excluding semaglutide and tirzepatide from the 503B Bulks List. Comment period closes June 29.
The Enforcement Reality
The FDA confirmed it is now proactively scanning telehealth websites for misleading GLP-1 marketing claims. In warning letters issued February 20, 2026, the FDA disclosed it had reviewed company websites months before sending enforcement actions. A September 2025 executive order shifted the agency from reactive complaint handling to active digital surveillance of pharmaceutical advertising.
In Q1 2026 alone, the FDA issued 40+ warning letters and 100+ cease-and-desist letters in the compounded weight-loss category. CDER warning letters jumped 50% in FY 2025; 22% of them went to telehealth platforms marketing compounded drug products with misleading claims.
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — a structural shutdown of the legal pathway 503B outsourcing facilities use to compound these medications at scale. The marketing-compliance issues that trigger warning letters arrive first in a sequence that ends with the supply pipeline becoming illegal.
If your website has compliance violations today, the FDA may already be documenting them.
“It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action.”
“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.”
The Timeline Is Accelerating
Every entry below is a public regulatory or corporate event. Every one is verifiable. The campaign is not slowing down.
FDA sends 55 warning letters to telehealth companies — plus roughly 100 cease-and-desist letters in the same week.
FTC settles with NextMed for $150,000 over unsubstantiated GLP-1 weight-loss claims. First major FTC GLP-1 telehealth enforcement action.
NAD rules against Willow Health Services — studies of FDA-approved drugs cannot substantiate claims for compounded alternatives. Willow refused to comply; case referred to state Attorneys General.
FDA warns Boothwyn Pharmacy for insanitary compounding conditions — escalation from marketing enforcement to physical-facility enforcement.
Hims launches a $49/month compounded oral semaglutide product.
HHS refers Hims to the Department of Justice for potential FDCA violations.
Novo Nordisk sues Hims for patent infringement on the compounded oral semaglutide product.
FDA sends 30 more warning letters to telehealth companies in a single day. Made public March 3.
Hims settles with Novo Nordisk — stops advertising compounded GLP-1s and projects a $65M Q1 revenue impact from the transition.
FDA warns 7 peptide retailers (made public April 7). 'Research Use Only' disclaimers do not cure violations when therapeutic effects are described.
FDA clarifies the 'essentially a copy' policy — 4-prescription-per-month soft cap for 503A compounders. No telehealth platform can lawfully scale on its 503A network.
FTC and DOJ move to seize Zealthy. Federal prosecutors say the action will 'likely spell the end of Zealthy.'
FDA proposes permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Comment period closes June 29, 2026.
The next enforcement action could target your website. ClinicShield catches it first.
The Chain Reaction
A single compliance violation can trigger a cascade that destroys revenue in 60 days.
15-day deadline to respond or face seizure
Appears when patients Google your name
Industry blogs and newsletters report it
Stripe/PayPal account termination
Google and Meta ads shut down
40-70% decline in 60 days
15-day deadline to respond or face seizure
Appears when patients Google your name
Industry blogs and newsletters report it
Stripe/PayPal account termination
Google and Meta ads shut down
40-70% decline in 60 days
Companies report revenue declines of 40-70% within 60 days of receiving a public warning letter. The warning letter itself is just the beginning.
These are not hypothetical chain reactions
A publicly traded telehealth company with hundreds of millions in revenue received a DOJ referral, a Novo Nordisk patent lawsuit, and a $65M quarterly revenue impact from the compounded GLP-1 enforcement wave. Within six weeks, the company stopped advertising compounded products entirely.
The FTC and DOJ moved to seize Zealthy — a telehealth company — with federal prosecutors stating the action would 'likely spell the end of Zealthy.' Allegations included subscription deception, NPI misuse, and non-clinician prescribing.
How ClinicShield Works
Our AI-powered engine analyzes every page of your website against 110 compliance rules derived from FDA regulations, FTC guidance, state laws, advertising platform policies, and HIPAA requirements.
We check the same violation patterns the FDA cited in 100+ warning letters — sameness claims, implied approval, missing disclosures, brand name misuse, own-name product labeling, and more.
You receive a detailed compliance report showing every violation found, with the exact text from your site and which FDA, FTC, state, or platform rule each violation breaks.
Each finding includes real warning letter precedents where the same violation was cited, plus your overall compliance risk score and a prioritized action list.
For every violation, we provide the exact compliant replacement language you can copy directly onto your site. No guessing, no ambiguity.
Need help implementing? Our compliance team handles it for you — from single-page fixes to full website rewrites.
What We Detect
Every rule is mapped to real enforcement actions — not theoretical compliance checklists, but the actual patterns regulators are actively pursuing.
What a Compliance Scan Reveals
Three of the 41 violations identified in a recent scan of a mid-size DTC telehealth company. Every finding includes the exact violating text and the recommended fix.
“Our patients lost an average of 22.9% of their body weight over 68 weeks of treatment with semaglutide.”
Remove or reattribute clinical data. Add FDA disclaimer: 'This is a compounded medication and is not FDA-approved. Clinical trial data referenced is for FDA-approved branded semaglutide products and may not apply to compounded alternatives.'
“No named compounding pharmacy identified on any product page or checkout flow.”
Add prominent disclosure on every product page and at checkout: 'Compounded by [Pharmacy Name], a [State]-licensed 503A compounding pharmacy. This is a personalized prescription product that has not been evaluated or approved by the FDA.'
“I lost 47 pounds in 4 months on this program — it changed my life.”
Add adjacent disclaimer for each testimonial: 'Individual results vary. This testimonial reflects one person's experience and is not representative of typical outcomes. Compounded GLP-1 medications have not been evaluated by the FDA for safety or efficacy.'
Each ClinicShield report contains 30-40 findings on average, organized by severity, with rule citations, page URLs, and copy-ready replacement language.
What Our Scans Reveal
of non-warned companies have at least one compliance violation
missing compounding pharmacy disclosure
of FDA-warned companies STILL have violations on their websites
The average telehealth company has 7+ compliance violations at first scan. Companies that undergo deep analysis average 38 findings across FDA, FTC, state, platform, and payment processor rules.
Your competitors are getting scanned. Many have already been warned. Are you confident your website is clean?
Services
vs. $5,000-25,000 for a healthcare attorney compliance review
$3,000 – 5,000
Just received a warning letter? We help you respond within the 15-day deadline.
About ClinicShield
ClinicShield was founded by Chris Trovato after the FDA sent 30 warning letters to telehealth companies in a single day on February 20, 2026 — the third major enforcement wave in six months. It was immediately clear the industry lacked proactive compliance infrastructure: most companies only hear about violations after the warning letter arrives and the 15-day clock is running.
Chris’s background is in healthcare marketing and regulatory research, with a focus on DTC pharmaceutical compliance. ClinicShield is the result of cataloging every public FDA warning letter from December 2024 through May 2026, reverse-engineering the exact violation patterns regulators are citing, and building an AI scanner that catches them before the FDA does.
The product is deliberately narrow: one problem, one audience, one outcome. Clean websites, kept clean.
Find out if your website has the same violations the FDA cited in 100+ warning letters — before they find you.